Generalized pustular psoriasis (GPP) may have therapies in a few years; how patients define remission in psoriatic arthritis (PsA).
Generalized pustular psoriasis (GPP) might be considered “as a rare, angrier variant of psoriasis,” according to a dermatologist presenting at a recent symposium.
However, Dermatology Times reported that there are no FDA-approved therapies for the disease; current treatments are off-label. That means they aren’t as accessible to patients given insurance policies around off-label use, said Bruce Strober, MD, PhD, cofounder of Central Connecticut Dermatology in Cromwell and clinical professor of dermatology at Yale School of Medicine in New Haven, Connecticut.
At the Symposium for Inflammatory Skin Disease last month, he spoke about targeted drugs that are in the early stages of development for GPP, including imsidolimab and spesolimab, both of which inhibit interleukin (IL)-36R; they are currently showing promise in phase 1 and phase 2 trials, he said.
Severe GPP can cause diffuse sterile pustules, significant skin pain, and systemic complaints such as fever, fatigue, and metabolic abnormalities.
Read more about the report in Dermatology Times.
Disease impact and disease activity are factors identified with the concept of patient-defined remission in psoriatic arthritis (PsA), according to a recent study.
Reported by Rheumatology Network, researchers used study data from ReFlaP data, an international PsA study. In PsA, the treatment goal is remission (REM) or low disease activity (LDA), but information about what patients think about REM is lacking.
In patients with PsA, patient-defined “remission” (REM) and low disease activity (LDA) are largely dominated by disease impact, including pain, as well as disease activity, chronicity and age, comorbidities, and symptoms related to other conditions, according to the results.
Read more about the study in Rheumatology Network.
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial
April 10th 2025New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen